Entera Bio Ltd.
ENTX Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 26, 2026
$2.86
KIRA · Stoqly’s AI analyst, in plain words
- Entera Bio Ltd. had $0.0M of revenue in fiscal 2025, down 76.8% on the year before. Over five years, revenue changed −35.1% a year on average.
- Its operating margin was −27,450.0%, down 22,154.4 pts: of every 100 in sales, about −27,450 is left after running the business.
- Entera Bio Ltd. lost $11.4M in fiscal 2025. From fiscal 2020 to 2025, diluted EPS grew −17.9% a year.
- Free cash flow was −$7.5M in fiscal 2025, −17,802.4% of revenue.
Market cap
$144M
P/E
8.4x
Revenue
$0.0M
Net income
−$11.4M
Free cash flow
−$7.5M
Operating margin
−27,450.0%
Entera Bio Ltd. in 30 seconds · fiscal 2025
Are sales growing?
−76.8%
No. Sales fell 76.8% last year.
Does it make a profit?
−27,235.7%
No. It lost money last year.
Does profit turn into cash?
−17,802.4%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 8
Weak. It passes 2 of 8 health tests.
How is the share priced?
8.4x
One share costs 8.4 times its yearly profit per share.
What Entera Bio Ltd. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 27, 2026
- Legal name
- Entera Bio Ltd.
- CIK
- 0001638097
Entera Bio Ltd. · ENTX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.6M | $0.1M | $0.0M | $0.2M | $0.0M |
| Revenue growth | 56.4% | −76.5% | −100.0% | — | −76.8% |
| Gross margin | 34.7% | 24.6% | — | 5.0% | 0.0% |
| Operating margin | −2,139.6% | −9,714.2% | — | −5,295.6% | −27,450.0% |
| Net income | −$12.2M | −$13.1M | −$8.9M | −$9.5M | −$11.4M |
| Net margin | −2,134.3% | −9,754.5% | — | −5,271.3% | −27,235.7% |
| Diluted EPS | $0.47 | $0.45 | $0.31 | $0.25 | $0.25 |
| Cash | |||||
| Cash from operations | −$9.1M | −$12.5M | −$7.3M | −$6.8M | −$7.4M |
| Capital expenditure | $0.0M | $0.0M | $0.0M | $0.0M | $0.1M |
| Free cash flow | −$9.1M | −$12.5M | −$7.3M | −$6.8M | −$7.5M |
| FCF margin | −1,590.2% | −9,362.7% | — | −3,768.5% | −17,802.4% |
| Share count change | 41.9% | 10.2% | 0.7% | 29.8% | 22.7% |
| Debt and strength | |||||
| Cash and short-term investments | $24.9M | $12.3M | $11.0M | $8.7M | $7.1M |
| Shareholders' equity | $22.6M | $11.8M | $10.4M | $8.1M | $13.1M |
| Current ratio | 8.0x | 9.6x | 10.3x | 7.6x | 6.9x |
| Returns and quality | |||||
| Return on equity | −81.0% | −76.2% | −80.3% | −103.3% | −108.0% |
| Return on tangible equity | −54.0% | −111.2% | −85.6% | −118.1% | −87.3% |
| Piotroski F-score | 4 | 2 | 3 | 2 | 2 |
| Altman Z'' | −1.0 | −15.6 | −20.4 | −34.5 | −20.3 |
Insiders bought, 12 months
$0.1M
5 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Entera Bio Ltd. · ENTX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $2.86 a share, the company is worth $144M: 8.4 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001638097). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.